CGCCanopy Growth Corporation
What is the market doing?
No clear lean: nothing decisive, though in a downtrend (−34% vs 200-day).
In a downtrend, below its 50- and 200-day averages. Oversold (RSI 15). Price is −34% vs its 200-day average.
Moderately shorted, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How CGC is trading
Canopy Growth Corporation is −49% over the past year while the S&P 500 is +16%: 65 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −34%
vs 200-day average · a clear downtrend
- RSI (14)
- 15
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 65%
Below its 52-week high
Details›
- Last close2026-10-23
- $0.67
- 1 monthS&P 500 −0.94%
- −28%
- 1 yearS&P 500 +16%
- −49%
- 5 yearsS&P 500 +86%
- −99%
- vs 50-day average$0.91
- −26%
- 52-week high
- $1.92
- 52-week low
- $0.66
- Annualised volatility
- 99%
- Insider selling, net, 6 monthsForms 3/4/5 to 2026-10-22
- $238K
| Year | Return |
|---|---|
| 2026 (year to date) | −41% |
| 2025 | −58% |
| 2024 | −46% |
| 2023 | −78% |
| 2022 | −74% |
| 2021 | −65% |
| 2020 | +17% |
| 2019 | −22% |
| 2018 | +14% |
| 2017 | +247% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 6 of 10 | +15% |
| Feb | 10 | 2 of 10 | −13% |
| Mar | 10 | 3 of 10 | +7.3% |
| Apr | 10 | 5 of 10 | +7.5% |
| May | 10 | 2 of 10 | −11% |
| Jun | 10 | 3 of 10 | −14% |
| Jul | 11 | 5 of 11 | +1.2% |
| Aug | 11 | 6 of 11 | +14% |
| Sep | 11 | 4 of 11 | −2.4% |
| Oct | 11 | 4 of 11 | +5.0% |
| Nov | 10 | 3 of 10 | +9.1% |
| Dec | 10 | 2 of 10 | −7.3% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.
Drug Manufacturers, Specialty & Generic
Ranks #26 of 39 by RyuScore